Di Yi Cai Jing·2026-02-26 14:27Core Insights - Eli Lilly's orforglipron has demonstrated superior efficacy compared to oral semaglutide in a head-to-head study for type 2 diabetes management, showing a 2.2% reduction in A1C levels versus 1.4% for semaglutide [1][2] - The study also indicated that participants taking orforglipron experienced an average weight loss of 8.9 kg (9.2%), compared to 5.0 kg (5.3%) for those on semaglutide, representing a 73.6% higher relative weight loss [1][2] Company Developments - Orforglipron, discovered by a collaboration between Chinese and foreign pharmaceutical companies, has been submitted for regulatory approval in over 40 countries, with a decision expected in the U.S. by Q2 2026 for obesity indications [2] - Oral semaglutide, developed by Novo Nordisk, is the first approved oral GLP-1 medication, with both glycemic control and weight loss indications approved in the U.S. and glycemic control approved in China [2] Industry Trends - The GLP-1 sector is experiencing a competitive landscape, with a focus on oral formulations, ultra-long-acting agents, and multi-target agonists to enhance patient experience and treatment efficacy [2] - Oral medications are perceived to have advantages over injectable GLP-1 drugs in terms of convenience and patient acceptance [2] Pricing Strategies - Novo Nordisk has announced significant price reductions for oral semaglutide in various markets, including a planned price drop in the U.S. to $675 per month starting January 1, 2027 [2] - In China, recent price adjustments have seen the cost of oral semaglutide drop by approximately 20%, with the 7 mg formulation reduced from 600 RMB to 480 RMB per box [3]